Hims & Hers Health (NYSE:HIMS) Trading 2.5% Higher

Hims & Hers Health, Inc. (NYSE:HIMS) shares rose 2.5% during trading on Thursday . The stock traded as high as $16.06 and last traded at $15.81. Approximately 2,415,943 shares traded hands during trading, a decline of 69% from the average daily volume of 7,861,309 shares. The stock had previously closed at $15.43.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on HIMS shares. Bank of America increased their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Piper Sandler reissued a “neutral” rating and set a $18.00 target price on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Finally, Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $20.00.

Hims & Hers Health Price Performance

The firm has a fifty day moving average of $20.80 and a 200 day moving average of $16.11. The stock has a market capitalization of $3.37 billion, a price-to-earnings ratio of -1,598.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The firm’s quarterly revenue was up 51.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.03) earnings per share. Research analysts predict that Hims & Hers Health, Inc. will post 0.2 EPS for the current year.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,502 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $17.33, for a total transaction of $43,359.66. Following the completion of the transaction, the insider now owns 156,855 shares in the company, valued at approximately $2,718,297.15. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider Soleil Boughton sold 2,502 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $17.33, for a total transaction of $43,359.66. Following the completion of the sale, the insider now directly owns 156,855 shares in the company, valued at $2,718,297.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Melissa Baird sold 16,784 shares of Hims & Hers Health stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $17.00, for a total transaction of $285,328.00. Following the sale, the chief operating officer now directly owns 585,800 shares in the company, valued at approximately $9,958,600. The disclosure for this sale can be found here. In the last quarter, insiders have sold 974,404 shares of company stock valued at $19,365,507. 17.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC grew its stake in shares of Hims & Hers Health by 103.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 43,662 shares of the company’s stock valued at $389,000 after buying an additional 22,170 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Hims & Hers Health by 5.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after buying an additional 1,561 shares during the period. Russell Investments Group Ltd. increased its holdings in Hims & Hers Health by 30.7% in the 4th quarter. Russell Investments Group Ltd. now owns 167,328 shares of the company’s stock valued at $1,489,000 after purchasing an additional 39,337 shares during the last quarter. Certuity LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at $109,000. Finally, Oder Investment Management LLC purchased a new stake in shares of Hims & Hers Health in the 4th quarter valued at $176,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.